"Patients with MS on natalizumab ","n = 20 "
Time on natalizumab prior to study,16.6 ± 10.9 (2.8– 41.3)
entry (months),
Age (years),38.5 ± 7.4 (22.9– 55.1)
Women,n = 14 (70%)
Clinical course,
Relapsing– remitting MS,n = 18 (90%)
Progressive forms of MS^{∗},n = 2 (10%)
Brain gadolinium-enhancing,n = 2 (10%)
lesions present,
Disease duration (years)^{†},9.7 ± 4.3 (1.9– 20.2)
Expanded Disability Status Scale,2.3 ± 2.0 (0– 6.5)
score,
Timed 25-foot walk (s),6.1 ± 3.4 (3.9– 17.0)
